Introduction/Background Endometrial cancer is one of the most common gynecological cancers, and its treatment involves hysterectomy, salpingo-oophorectomy, and lymph nodal staging. In the modern era, surgical treatment cannot ignore the aesthetic result, especially for young women. According to this view, in 2013, the FDA approved robotic single-site (RSS) surgery. RSS has been introduced in minimally invasive surgery as an acceptable alternative to laparoendoscopy surgery in a single site (LESS) to combine the advantages of robotic surgery with the aesthetic result of a single incision and to overcome LESS limitations in terms of loss of door triangulation, and instrumental collisions This study aims to review the existing studies on RSS hysterectomy in patients with endometrial cancer and verify its safety and feasibility

Results Seven studies met the inclusion criteria, and 258 patients were included with a median age of 53 to 64 years and a BMI of 24.6 to 27 kg/m2. The median pre-surgical time ranged from 8 to 12.5 min, the median operative time ranged from 90 to 175 min, the median console time from 46 to 136 min, and the median blood loss from 50 to 145 ml. No intraoperative complications were observed; only a study reported a conversion rate of 1,25%. The median hospital stay ranged from 2 to 3 days. The postoperative complication rate was estimated at 5.42%.

Conclusion Our findings support the safety and feasibility of robotic single-site technique in endometrial cancer treatment, which was associated with short operative times and acceptable complication rates. In addition, RSS allows you to combine the advantages of robotic surgery with the aesthetic result of a single incision. Further studies are warranted to confirm results and determine the optimal approach for minimally invasive surgery (MIS) in endometrial cancer.

Disclosures The authors made no disclosures. No specific funding was disclosed.